Wenyi Liu

Dr. Wenyi Liu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2024 in European Journal of Surgical Oncology
Verified
Journal Article
Open access
ZHZhinuan Hong
Zhinuan Hong
SXShuhan Xie
Shuhan Xie
HXHui Xu
Hui Xu
SKSunkui Ke
Sunkui Ke
WLWenyi Liu
Wenyi Liu
MKMingqiang Kang
Mingqiang Kang
To determine the prognostic and survival surrogate value of major pathologic response (MPR) in esophageal squamous cell carcinoma (ESCC) patients undergoing neoadjuvant chemotherapy/chemoimmunotherapy(nCT/nICT) and surgery. A retrospective multi-center study cohort study enrolled 305 ESCC patients who underwent neoadjuvant chemotherapy/chemoimmunotherapy followed by esophagectomy. Endpoints included recurrence-free survival (RFS), locoregional recurrence-free survival(L-RFS), distant metastasis-free survival(D-MFS), and recurrence patterns. The Cox regression analysis and Harrell's C-index were used to analyze survival differences and surrogate endpoints. The Kaplan-Meier method was used for the subgroup analysis in two subgroups(the patients receiving nICT and patients receiving nCT) and the prognostic value analysis of adjuvant therapy in non-MPR and MPR patients. Of the 305 patients, 105 achieved MPR, demonstrating a significantly improved RFS (P value < 0.001), L-RFS (P value < 0.001), and D-MFS (P value = 0.003). MPR was identified as an independent risk factor for RFS(HR:0.415, 95%CI:[0.227, 0.759], P value = 0.004) and demonstrated equal predictive capacity to be a surrogate of survival endpoints with T stage and N stage(Harrell's C-index: 0.613). In subgroup analysis, patients with MPR showed better survival outcomes in subgroups that received neoadjuvant chemoimmunotherapy (P value = 0.012) and neoadjuvant chemotherapy(P value < 0.001). Additionally, adjuvant therapy did not confer additional survival benefits to both MPR and non-MPR patients. Compared with patients who achieved MPR, non-MPR patients exhibited a higher recurrence rate, although the recurrence sites were similar between the two groups. MPR can serve as an independent prognostic factor and a surrogate of survival endpoints in ESCC patients undergoing nCT/nICT. Besides, as a potential indicator for postoperative management, MPR can provide reference basis and evidence support in clinical practice.

3 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
WLWenyi Liu
Wenyi Liu
BZBaihua Zhang
Baihua Zhang
CWChunguang Wang
Chunguang Wang
XYXin Yu
Xin Yu
LDLongde Du
Longde Du
MKMingqiang Kang
Mingqiang Kang
Esophageal cancer (EC) continues to pose a major global health burden, ranking as the ninth most common malignancy and sixth leading cause of cancer mortality, with over 600,000 new cases and 500,000 deaths annually as of 2025. While esophagectomy has long been the standard for curative intent in resectable disease, organ preservation strategies have advanced significantly, offering viable alternatives for patients with locally advanced esophageal squamous cell carcinoma (ESCC) or those unsuitable for surgery due to comorbidities. These approaches encompass definitive chemoradiotherapy (dCRT), neoadjuvant chemoradiotherapy (nCRT) followed by active surveillance (“watch-and-wait”), and innovative integrations of immunotherapy and targeted therapies. This narrative review synthesizes evidence from recent clinical trials, systematic reviews, and international guidelines up to 2025, demonstrating that organ-sparing protocols can achieve comparable overall survival (OS) rates—often exceeding 50% at 5 years in selected cohorts-while substantially enhancing quality of life (QoL) by preserving esophageal function. For instance, the SANO trial (2025) confirmed non-inferiority of active surveillance post-nCRT, with 2-year OS of 74% versus 71% for standard surgery. Key challenges include imprecise response assessment, locoregional recurrences (20–30%), and treatment-related toxicities such as esophageal strictures. Emerging trials like ESOSTRATE and PALACE3 are evaluating immunotherapy-enhanced regimens, potentially expanding organ preservation to esophageal adenocarcinoma (EAC). With genomic biomarkers and novel modalities like proton therapy, personalized organ preservation promises to broaden applicability, reduce morbidity, and improve outcomes across histological subtypes. Additionally, recent studies emphasize the role of liquid biopsies, such as circulating tumor DNA (ctDNA), in monitoring treatment response and guiding surveillance, potentially reducing the need for invasive procedures and improving detection of minimal residual disease. The aim of this review is not only to summarize recent trials but to synthesize them into an operational framework that clinicians and researchers can apply: a decision algorithm for selecting organ preservation candidates. This is the novel element that distinguishes this work from prior narrative reviews.

22 May 2025 in Research Square
Verified
Preprint
Open access
PDF file
WLWenyi Liu
Wenyi Liu
ZSZhilin Sui
Zhilin Sui
CWChunguang Wang
Chunguang Wang
YDYoujun Deng
Youjun Deng
SCSonghua Cai
Songhua Cai
BZBaihua Zhang
Baihua Zhang
Background The application of neoadjuvant immunotherapy combined with chemotherapy in intermediate and high-risk resectable non-small cell lung cancer (NSCLC) is increasing, with some patients achieving pathological complete response (pCR). However, there is no effective tool for clinical precision prediction of pCR. This study aims to integrate clinical data to develop and construct a nomogram model capable of predicting the risk of pCR in NSCLC patients following neoadjuvant chemotherapy combined with immunotherapy, thereby providing a reference for individualized treatment decisions. Methods A retrospective analysis was conducted on patients with resectable NSCLC who underwent neoadjuvant chemotherapy combined with immunotherapy between 2019 and 2022. Inclusion criteria were as follows: diagnosis of NSCLC (stages IIB–IIIB), completion of neoadjuvant chemotherapy and immunotherapy followed by surgical resection, and a definitive postoperative pathological assessment. Clinical parameters such as age, gender, smoking history, comorbidities, neoadjuvant treatment regimens, and treatment-related adverse events were collected. Univariate and multivariate logistic regression analyses were performed to identify predictive factors for pCR, which were subsequently used to construct a nomogram model. Results A total of 179 patients were included in the study, comprising 92 cases (51.4%) in the pCR group and 87 cases (48.6%) in the non-pCR group. Multivariate analysis identified the following factors as significantly associated with pCR (P < 0.05): pathological type, family history of tumors, duration of smoking cessation, age, and number of neoadjuvant treatment cycles. A multivariate logistic regression model incorporating these factors demonstrated an area under the curve (AUC) of 0.709 (95% CI: 0.633–0.785), indicating good predictive performance. The calibration curve showed strong agreement between predicted probabilities and observed outcomes. Conclusions Based on real clinical data, this study developed and constructed a nomogram to predict pCR in NSCLC patients after neoadjuvant chemotherapy combined with immunotherapy. This tool not only performs well in terms of discrimination and calibration but also has potential clinical application value, providing new ideas and basis for the formulation of individualized treatment strategies.